

Author Index Volume 13 (2013)

The issue number is given in front of the pagination

- Ai, B., see Nie, X. (6) 433–440
Akyol, M., see Dirican, A. (1) 11–20
Alacacioglu, A., see Dirican, A. (1) 11–20
Almasi, S., see Milanizadeh, S. (6) 427–432
Aloe, R., see Gallotta, A. (4) 227–234
An, S.-J., see Bai, X.-Y. (1) 37–47
Araujo-Perez, F., see Kang, M. (5) 359–366
Arora, V.K., see Sharma, T. (4) 243–251
Avci, A., see Dirican, A. (1) 11–20
Azimzadeh, P., see Milanizadeh, S. (6) 427–432
- Bai, X.-Y., J.-Y. Lin, X.-C. Zhang, Z. Xie, H.-H. Yan, Z.-H. Chen, C.-R. Xu, S.-J. An, G.-M. Sheng and Y.-L. Wu, High expression of truncated GLI3 is associated with poor overall survival in patients with non-small cell lung cancer (1) 37–47
Bai, Z., see Zhao, X. (1) 1–10
Banerjee, B.D., see Sharma, T. (4) 243–251
Bao, Q.-L., see Li, J. (1) 49–58
Bayoglu, I.V., see Dirican, A. (1) 11–20
Bing, Z., see Su, Y. (5) 367–375
Bobrowska-Korczak, B., D. Skrajnowska and A. Tokarz, Effect of zinc and copper supplementation on the prognostic value of urinary 5-methyl-2'-deoxycytidine in DMBA-induced carcinogenesis in rats (6) 403–410
Brierley, G.V., I.K. Priebe, L. Purins, K.Y.C. Fung, B. Tabor, T. Lockett, E. Nice, P. Gibbs, J. Tie, P. McMurrick, J. Moore, A. Ruskiewicz, A. Burgess and L.J. Cosgrove, Serum concentrations of brain-derived neurotrophic factor (BDNF) are decreased in colorectal cancer patients (2) 67–73
Brierley, G.V., see Fung, K.Y.C. (2) 75–79
Burgess, A., see Brierley, G.V. (2) 67–73
Burgess, A., see Fung, K.Y.C. (2) 75–79
- Cai, H., see Xu, T. (6) 411–415
Can, A., see Dirican, A. (1) 11–20
Castañeda-Lopez, M.E., see Martinez-Fierro, M.L. (4) 235–241
Castruita-de la Rosa, C., see Martinez-Fierro, M.L. (4) 235–241
Çekiç, E., Ö. Sürmelioglu, Ö. Tarkan, S. Özdemir, A. Uğuz and M. Kıroğlu, Investigation of recurrence risk in laryngeal cancer following laser surgery (6) 441–446
Cervantes-Villagrana, A.R., see Martinez-Fierro, M.L. (4) 235–241
Chakrabarti, J., see Mitra, S. (4) 201–213
Chang, C.-C., see Tsai, M.-S. (5) 307–313
Chen, C., J. Liu and G. Xu, Overexpression of PIWI proteins in human stage III epithelial ovarian cancer with lymph node metastasis (5) 315–321
Chen, C.-M., see Xu, P.-W. (2) 115–122
Chen, D., see Ma, R.-L. (6) 447–455
Chen, H.-C., see Huang, M.-Y. (4) 269–279
Chen, J., see Li, H. (5) 337–343
Chen, P., see Li, J. (1) 49–58
Chen, W., see Lv, M. (5) 395–401
Chen, W., see Xu, X.-L. (2) 105–113
Chen, Z.-H., see Bai, X.-Y. (1) 37–47
Cheng, G., see Nie, X. (6) 433–440
Cheng, H., see Zhang, Y. (4) 299–305
Chung, K., see Hanada, S. (4) 289–298
Chung, K., see Komatsu, H. (3) 171–180
Conzen, S.D., see Obeid, E.I. (3) 161–169
Cosgrove, L.J., see Brierley, G.V. (2) 67–73
Cosgrove, L.J., see Fung, K.Y.C. (2) 75–79
- Daly, D.S., see Jin, H. (3) 193–200
Damavand, B., see Milanizadeh, S. (6) 427–432
Das, S., see Mitra, S. (4) 201–213
Dehaghani, A.S., see Malekzadeh, M. (6) 417–425
Delgado-Enciso, I., see Martinez-Fierro, M.L. (4) 235–241
Demir, L., see Dirican, A. (1) 11–20
Di Palo, M., see Gallotta, A. (4) 227–234
Ding, S., see Liu, S. (5) 345–349

- Dirican, A., N. Ekinici, A. Avci, M. Akyol, A. Alacacioglu, Y. Kucukzeybek, I. Somali, C. Erten, L. Demir, A. Can, I.V. Bayoglu, B. Koyuncu, E. Ulger and M.O. Tarhan, The effects of hematological parameters and tumor-infiltrating lymphocytes on prognosis in patients with gastric cancer (1) 11–20
- Doroudchi, M., see Malekzadeh, M. (6) 417–425
- Du, W., X. Ma, W. Kong, T. Liu, B. Wei, J. Yu, Y. Li, J. Huang, Z. Li and L. Liu, Association between rs11614913 polymorphism in miR-196a2 and colorectal cancer risk: A meta-analysis (6) 457–464
- Duan, H., see Jiang, L. (6) 465–470
- Ekinici, N., see Dirican, A. (1) 11–20
- Erten, C., see Dirican, A. (1) 11–20
- Eskandari-Nasab, E., M. Hashemi, S.-S. Hasani, M. Omrani, M. Taheri and M.-A. Mashhadi, Association between HLA-G 3'UTR 14-bp ins/del polymorphism and susceptibility to breast cancer (4) 253–259
- Eubank, T.D., see Yang, E.V. (3) 155–160
- Fan, L., see Zhang, Y. (4) 299–305
- Fassina, G., see Gallotta, A. (4) 227–234
- Feng, X., see Zhong, H. (1) 29–35
- Feng, Y., see Zhong, H. (1) 29–35
- Ferretti, S., see Gallotta, A. (4) 227–234
- Fiszer-Kierzkowska, A., see Mazurek, A.M. (5) 385–394
- Fu, X., see Su, Y. (5) 367–375
- Fung, K.Y.C., I. Priebe, L. Purins, B. Tabor, G.V. Brierley, T. Lockett, E. Nice, P. Gibbs, J. Tie, P. McMurrick, J. Moore, A. Ruzkiewicz, A. Burgess and L.J. Cosgrove, Performance of serum lipocalin 2 as a diagnostic marker for colorectal cancer (2) 75–79
- Fung, K.Y.C., see Brierley, G.V. (2) 67–73
- Gai, J., see Li, Z. (3) 181–192
- Galanko, J.A., see Kang, M. (5) 359–366
- Gallotta, A., F. Ziglioli, S. Ferretti, U. Maestroni, M. Moretti, R. Aloe, C. Gnocchi, M. Di Palo and G. Fassina, A novel algorithm for the prediction of prostate cancer in clinically suspected patients (4) 227–234
- Gao, F., see Li, Z. (3) 181–192
- Gao, X., see Jiang, L. (6) 465–470
- Garza-Veloz, I., see Martinez-Fierro, M.L. (4) 235–241
- Ge, W., see Ma, R.-L. (6) 447–455
- Ghaderi, A., see Malekzadeh, M. (6) 417–425
- Gibbs, P., see Brierley, G.V. (2) 67–73
- Gibbs, P., see Fung, K.Y.C. (2) 75–79
- Głowacki, G., see Mazurek, A.M. (5) 385–394
- Gnocchi, C., see Gallotta, A. (4) 227–234
- Gomez-Guerra, L., see Martinez-Fierro, M.L. (4) 235–241
- Gong, P., see Li, Z. (3) 181–192
- Guan, J., see Zhang, Y. (4) 299–305
- Gupta, S., see Sharma, T. (4) 243–251
- Haghighi, M.M., see Milanizadeh, S. (6) 427–432
- Hajirashid, M., see Zhang, Y. (4) 299–305
- Han, X., see Wang, J. (2) 89–97
- Hanada, S., A. Kakehashi, N. Nishiyama, M. Wei, S. Yamano, K. Chung, H. Komatsu, H. Inoue, S. Suehiro and H. Wanibuchi, Myristoylated alanine-rich C-kinase substrate as a prognostic biomarker in human primary lung squamous cell carcinoma (4) 289–298
- Hanada, S., see Komatsu, H. (3) 171–180
- Hao, J.-J., see Zhou, H.-T. (4) 281–288
- Hao, X., see Wang, P. (2) 123–130
- Hasani, S.-S., see Eskandari-Nasab, E. (4) 253–259
- Hashemi, M., see Eskandari-Nasab, E. (4) 253–259
- He, X., see Li, Z. (3) 181–192
- Hu, Y.-M., see Li, J. (1) 49–58
- Huang, J., see Du, W. (6) 457–464
- Huang, M.-Y., H.-C. Chen, I-P. Yang, H.-L. Tsai, T.-N. Wang, S.-H.H. Juo and J.-Y. Wang, Tumorigenesis and tumor progression related gene expression profiles in colorectal cancer (4) 269–279
- Inoue, H., see Hanada, S. (4) 289–298
- Inoue, H., see Komatsu, H. (3) 171–180
- Izumi, N., see Komatsu, H. (3) 171–180
- Jain, S., see Sharma, T. (4) 243–251
- Jiang, B., see Wang, X. (2) 81–88
- Jiang, C., see Zhang, Y. (4) 299–305
- Jiang, H., see Zhang, Y. (6) 483–489
- Jiang, L., X. Gao, H. Duan and Z. Zhu, Association between PTEN IVS4 polymorphism and cancer risk: A meta-analysis (6) 465–470
- Jiang, Y.-Y., see Zhou, H.-T. (4) 281–288
- Jie, S., see Wang, W. (5) 351–357
- Jin, H., D.S. Daly, J.R. Marks and R.C. Zangar, Oxidatively modified proteins as plasma biomarkers in breast cancer (3) 193–200
- Jin, Y.-T., see Xu, P.-W. (2) 115–122
- Ju, L. and C. Zhou, Integrin beta 1 enhances the epithelial-mesenchymal transition in association with gefitinib resistance of non-small cell lung cancer (5) 329–336

- Juo, S.-H.H., see Huang, M.-Y. (4) 269–279
- Takehashi, A., see Hanada, S. (4) 289–298
- Takehashi, A., see Komatsu, H. (3) 171–180
- Kang, J.-H., T. Mori, H. Kitazaki, T. Niidome, K. Takayama, Y. Nakanishi and Y. Katayama, Serum protein kinase C α as a diagnostic biomarker of cancers (2) 99–103
- Kang, M., X.J. Shen, S. Kim, F. Araujo-Perez, J.A. Galanko, C.F. Martin, R.S. Sandler and T.O. Keku, Somatic gene mutations in African Americans may predict worse outcomes in colorectal cancer (5) 359–366
- Katayama, Y., see Kang, J.-H. (2) 99–103
- Kawczyński, R., see Mazurek, A.M. (5) 385–394
- Keku, T.O., see Kang, M. (5) 359–366
- Khanyaghma, M., see Milanizadeh, S. (6) 427–432
- Kim, S., see Kang, M. (5) 359–366
- Kıroğlu, M., see Çekiç, E. (6) 441–446
- Kitazaki, H., see Kang, J.-H. (2) 99–103
- Komatsu, H., A. Takehashi, N. Nishiyama, N. Izumi, S. Mizuguchi, S. Yamano, H. Inoue, S. Hanada, K. Chung, M. Wei, S. Suehiro and H. Wanibuchi, Complexin-2 (CPLX2) as a potential prognostic biomarker in human lung high grade neuroendocrine tumors (3) 171–180
- Komatsu, H., see Hanada, S. (4) 289–298
- Kong, W., see Du, W. (6) 457–464
- Koyuncu, B., see Dirican, A. (1) 11–20
- Kucukzeybek, Y., see Dirican, A. (1) 11–20
- Kuo, M.-L., see Tsai, M.-S. (5) 307–313
- Lazalde-Ramos, B.P., see Martinez-Fierro, M.L. (4) 235–241
- Li, H., K. Tang, L. Niu, Y. Liang, J. Li, J. Chen and K. Xu, Carcinoembryonic antigen as prognostic factor for metastatic non-small cell lung cancer by percutaneous cryosurgery (5) 337–343
- Li, H., see Wang, W. (5) 351–357
- Li, J., Q.-L. Bao, Y. Wang, Y.-M. Hu and P. Chen, Diagnostic value of the FHIT and p16 mRNA loss and the K-ras gene mutation in pleural fluids for malignant pleural effusion (1) 49–58
- Li, J., see Li, H. (5) 337–343
- Li, J., see Li, Z. (3) 181–192
- Li, W., K. Nichols, C.-A. Nathan and Y. Zhao, Mitochondrial uncoupling protein 2 is up-regulated in human head and neck, skin, pancreatic, and prostate tumors (5) 377–383
- Li, W., see Wang, P. (2) 123–130
- Li, Y., see Du, W. (6) 457–464
- Li, Y.Y., X.L. Ma, J.Y. Zhao, B.L. Zhang, J. Zhang and L. Liu, microRNA-210 as a Prognostic Factor in Patients with Breast Cancer: Meta-analysis (6) 471–481
- Li, Z., see Du, W. (6) 457–464
- Li, Z., X. He, S. Xing, J. Ni, W. Zhang, X. Xu, F. Gao, J. Gai, Z. Zhao, J. Li, P. Gong, G. Zhang and X. Zhang, Overexpression of Aldo-keto reductase family 1 B10 protein in ductal carcinoma in situ of the breast correlates with HER2 positivity (3) 181–192
- Liang, Y., see Li, H. (5) 337–343
- Liang, Y., see Wang, X. (2) 81–88
- Liang, Y., see Zhong, H. (1) 29–35
- Lin, D., see Wang, J. (2) 89–97
- Lin, J.-Y., see Bai, X.-Y. (1) 37–47
- Ling, Z.-Q., see Xu, X.-L. (2) 105–113
- Liu, J., see Chen, C. (5) 315–321
- Liu, L., see Du, W. (6) 457–464
- Liu, L., see Li, Y.Y. (6) 471–481
- Liu, S., P. Zhu, L. Zhang, S. Ding, S. Zheng, Y. Wang and F. Lu, Selection of reference genes for RT-qPCR analysis in tumor tissues from male hepatocellular carcinoma patients with hepatitis B infection and cirrhosis (5) 345–349
- Liu, T., see Du, W. (6) 457–464
- Liu, X.-N., see Xu, P.-W. (2) 115–122
- Lockett, T., see Brierley, G.V. (2) 67–73
- Lockett, T., see Fung, K.Y.C. (2) 75–79
- Lou, M., see Zhao, Y. (1) 59–66
- Lu, C., see Xu, R. (4) 215–226
- Lu, C., see Yin, H. (4) 261–267
- Lu, F., see Liu, S. (5) 345–349
- Lv, M., X. Zhu, W. Chen, J. Zhao and J. Tang, Searching for candidate microRNA biomarkers in detection of breast cancer: A meta-analysis (5) 395–401
- Ma, L., see Wang, J. (2) 89–97
- Ma, R.-L., L. Min, D. Chen, W.-P. Tao, W. Ge and Y.-G. Wu, N-acetyltransferase 2 phenotype and risk of esophageal cancer: A meta analysis (6) 447–455
- Ma, X., see Du, W. (6) 457–464
- Ma, X.L., see Li, Y.Y. (6) 471–481
- Maestroni, U., see Gallotta, A. (4) 227–234
- Malekzadeh, M., A.S. Dehaghani, A. Ghaderi and M. Doroudchi, IL-17A is elevated in sera of patients with poorly differentiated ovarian papillary serous cystadenocarcinoma (6) 417–425
- Malusecka, E., see Mazurek, A.M. (5) 385–394
- Mao, W.-M., see Xu, X.-L. (2) 105–113
- Marks, J.R., see Jin, H. (3) 193–200

- Martin, C.F., see Kang, M. (5) 359–366
- Martinez-Fierro, M.L., I. Garza-Veloz, A. Rojas-Martinez, R. Ortiz-Lopez, C. Castruita-de la Rosa, Y. Ortiz-Castro, B.P. Lazalde-Ramos, A.R. Cervantes-Villagrana, M.E. Castañeda-Lopez, L. Gomez-Guerra, I. Delgado-Enciso and A.A. Martinez-Torres, Positive association between vascular endothelial growth factor (VEGF) -2578 C/A variant and prostate cancer (4) 235–241
- Martinez-Torres, A.A., see Martinez-Fierro, M.L. (4) 235–241
- Mashhadi, M.-A., see Eskandari-Nasab, E. (4) 253–259
- Mazurek, A.M., A. Fiszler-Kierzkowska, T. Rutkowski, K. Skłodowski, M. Pierzyna, D. Śieglińska, G. Woźniak, G. Głowacki, R. Kawczyński and E. Małusecka, Optimization of circulating cell-free DNA recovery for KRAS mutation and HPV detection in plasma (5) 385–394
- McMurrick, P., see Brierley, G.V. (2) 67–73
- McMurrick, P., see Fung, K.Y.C. (2) 75–79
- Melhem-Bertrandt, A. and A.K. Sood, Editorial (3) 131–132
- Milanizadeh, S., M. Khanyaghma, M.M. Haghghi, S. Mohebbi, B. Damavand, S. Almasi, P. Azimzadeh and M. Zali, Molecular analysis of imperative polymorphisms of MLH1 gene in sporadic colorectal cancer (6) 427–432
- Min, L., see Ma, R.-L. (6) 447–455
- Mitra, S., S. Das and J. Chakrabarti, Systems Biology of Cancer Biomarker detection (4) 201–213
- Mizuguchi, S., see Komatsu, H. (3) 171–180
- Mohebbi, S., see Milanizadeh, S. (6) 427–432
- Moore, J., see Brierley, G.V. (2) 67–73
- Moore, J., see Fung, K.Y.C. (2) 75–79
- Moretti, M., see Gallotta, A. (4) 227–234
- Mori, T., see Kang, J.-H. (2) 99–103
- Nakanishi, Y., see Kang, J.-H. (2) 99–103
- Nathan, C.-A., see Li, W. (5) 377–383
- Ni, J., see Li, Z. (3) 181–192
- Nice, E., see Brierley, G.V. (2) 67–73
- Nice, E., see Fung, K.Y.C. (2) 75–79
- Nichols, K., see Li, W. (5) 377–383
- Nie, X., G. Cheng, B. Ai and S. Zhang, The tailored chemotherapy based on RRM1 immunohistochemical expression in patients with advanced non-small cell lung cancer (6) 433–440
- Niidome, T., see Kang, J.-H. (2) 99–103
- Nishiyama, N., see Hanada, S. (4) 289–298
- Nishiyama, N., see Komatsu, H. (3) 171–180
- Niu, L., see Li, H. (5) 337–343
- Obeid, E.I. and S.D. Conzen, The role of adrenergic signaling in breast cancer biology (3) 161–169
- Omrani, M., see Eskandari-Nasab, E. (4) 253–259
- Ortiz-Castro, Y., see Martinez-Fierro, M.L. (4) 235–241
- Ortiz-Lopez, R., see Martinez-Fierro, M.L. (4) 235–241
- Özdemir, S., see Çekiç, E. (6) 441–446
- Pan, J.-Q., see Xuan, S.-H. (5) 323–328
- Peng, L., see Wang, X. (2) 81–88
- Peng, X., see Su, Y. (5) 367–375
- Piao, Y., see Wang, P. (2) 123–130
- Pierzyna, M., see Mazurek, A.M. (5) 385–394
- Priebe, I., see Fung, K.Y.C. (2) 75–79
- Priebe, I.K., see Brierley, G.V. (2) 67–73
- Purins, L., see Brierley, G.V. (2) 67–73
- Purins, L., see Fung, K.Y.C. (2) 75–79
- Ramondetta, L.M., see Thaker, P.H. (3) 145–154
- Rojas-Martinez, A., see Martinez-Fierro, M.L. (4) 235–241
- Ruszkiewicz, A., see Brierley, G.V. (2) 67–73
- Ruszkiewicz, A., see Fung, K.Y.C. (2) 75–79
- Rutkowski, T., see Mazurek, A.M. (5) 385–394
- Sandler, R.S., see Kang, M. (5) 359–366
- Schuller, H.M., Effects of tobacco constituents and psychological stress on the beta-adrenergic regulation of non-small cell lung cancer and pancreatic cancer: Implications for intervention (3) 133–144
- Sharma, N., see Sharma, T. (4) 243–251
- Sharma, T., S. Jain, A. Verma, N. Sharma, S. Gupta, V.K. Arora and B.D. Banerjee, Gene Environment Interaction in Urinary Bladder cancer with special reference to organochlorine pesticide: A case control study (4) 243–251
- Shen, X.J., see Kang, M. (5) 359–366
- Shen, Y., see Wang, J. (2) 89–97
- Sheng, G.-M., see Bai, X.-Y. (1) 37–47
- Shi, F., see Zhou, H.-T. (4) 281–288
- Shi, Y., see Wang, J. (2) 89–97
- Shi, Z.-Z., see Zhou, H.-T. (4) 281–288
- Śieglińska, D., see Mazurek, A.M. (5) 385–394
- Skłodowski, K., see Mazurek, A.M. (5) 385–394
- Skrajnowska, D., see Bobrowska-Korczak, B. (6) 403–410
- Somali, I., see Dirican, A. (1) 11–20
- Sood, A.K., see Melhem-Bertrandt, A. (3) 131–132
- Sood, A.K., see Thaker, P.H. (3) 145–154

- Su, Y., J. Xiong, Z. Bing, X. Zeng, Y. Zhang, X. Fu and X. Peng, Identification of novel human glioblastoma-specific transcripts by serial analysis of gene expression data mining (5) 367–375
- Suehiro, S., see Hanada, S. (4) 289–298
- Suehiro, S., see Komatsu, H. (3) 171–180
- Sürmelioglu, Ö., see Çekiç, E. (6) 441–446
- Tabor, B., see Brierley, G.V. (2) 67–73
- Tabor, B., see Fung, K.Y.C. (2) 75–79
- Taheri, M., see Eskandari-Nasab, E. (4) 253–259
- Takayama, K., see Kang, J.-H. (2) 99–103
- Tan, C., see Xu, P.-W. (2) 115–122
- Tang, J., see Lv, M. (5) 395–401
- Tang, K., see Li, H. (5) 337–343
- Tang, Y., see Yin, H. (4) 261–267
- Tao, W.-P., see Ma, R.-L. (6) 447–455
- Tarhan, M.O., see Dirican, A. (1) 11–20
- Tarkan, Ö., see Çekiç, E. (6) 441–446
- Thaker, P.H., A.K. Sood and L.M. Ramondetta, Importance of adrenergic pathways in women's cancers (3) 145–154
- Tie, J., see Brierley, G.V. (2) 67–73
- Tie, J., see Fung, K.Y.C. (2) 75–79
- Tokarz, A., see Bobrowska-Korczak, B. (6) 403–410
- Tsai, H.-L., see Huang, M.-Y. (4) 269–279
- Tsai, M.-S., M.-L. Kuo, C.-C. Chang and Y.-T. Wu, The effects of exercise training on levels of vascular endothelial growth factor in tumor-bearing mice (5) 307–313
- Uğuz, A., see Çekiç, E. (6) 441–446
- Ulger, E., see Dirican, A. (1) 11–20
- Verma, A., see Sharma, T. (4) 243–251
- Wang, F., see Xu, R. (4) 215–226
- Wang, G., W. Wang, J. Zhou and X. Yang, Correlation between telomerase activity and matrix metalloproteinases 2 expression in gastric cancer (1) 21–28
- Wang, H., see Yin, H. (4) 261–267
- Wang, H., see Yin, H. (4) 261–267
- Wang, J., H. Yang, Y. Shen, S. Wang, D. Lin, L. Ma, X. Han and Y. Shi, Direct sequencing is a reliable assay with good clinical applicability for *KRAS* mutation testing in colorectal cancer (2) 89–97
- Wang, J., see Xu, R. (4) 215–226
- Wang, J., see Yin, H. (4) 261–267
- Wang, J.-Y., see Huang, M.-Y. (4) 269–279
- Wang, K., see Zhao, Y. (1) 59–66
- Wang, M.-R., see Zhou, H.-T. (4) 281–288
- Wang, P., Y. Piao, X. Zhang, W. Li and X. Hao, The concentration of CYFRA 21-1, NSE and CEA in cerebro-spinal fluid can be useful indicators for diagnosis of meningeal carcinomatosis of lung cancer (2) 123–130
- Wang, R., see Zhang, Y. (6) 483–489
- Wang, S., see Wang, J. (2) 89–97
- Wang, T.-N., see Huang, M.-Y. (4) 269–279
- Wang, W., H. Li, Y. Zhou and S. Jie, Peripheral blood microvesicles are potential biomarkers for hepatocellular carcinoma (5) 351–357
- Wang, W., see Wang, G. (1) 21–28
- Wang, W., see Wang, X. (2) 81–88
- Wang, X., B. Xia, Y. Liang, L. Peng, Z. Wang, J. Zhuo, W. Wang and B. Jiang, Membranous ABCG2 expression in colorectal cancer independently correlates with shortened patient survival (2) 81–88
- Wang, Y., see Li, J. (1) 49–58
- Wang, Y., see Liu, S. (5) 345–349
- Wang, Y., see Zhang, Y. (4) 299–305
- Wang, Z., see Wang, X. (2) 81–88
- Wanibuchi, H., see Hanada, S. (4) 289–298
- Wanibuchi, H., see Komatsu, H. (3) 171–180
- Wei, B., see Du, W. (6) 457–464
- Wei, M., see Hanada, S. (4) 289–298
- Wei, M., see Komatsu, H. (3) 171–180
- Woźniak, G., see Mazurek, A.M. (5) 385–394
- Wu, J., see Xu, T. (6) 411–415
- Wu, L., see Xu, R. (4) 215–226
- Wu, P., see Zhao, X. (1) 1–10
- Wu, Y.-G., see Ma, R.-L. (6) 447–455
- Wu, Y.-L., see Bai, X.-Y. (1) 37–47
- Wu, Y.-T., see Tsai, M.-S. (5) 307–313
- Xia, B., see Wang, X. (2) 81–88
- Xie, Z., see Bai, X.-Y. (1) 37–47
- Xing, S., see Li, Z. (3) 181–192
- Xiong, J., see Su, Y. (5) 367–375
- Xu, C.-R., see Bai, X.-Y. (1) 37–47
- Xu, G., see Chen, C. (5) 315–321
- Xu, H.-Y., see Xu, P.-W. (2) 115–122
- Xu, K., see Li, H. (5) 337–343
- Xu, P., see Xuan, S.-H. (5) 323–328
- Xu, P.-W., H.-Y. Xu, X.-N. Liu, C.-Y. Zhang, C. Tan, C.-M. Chen, H. Zhang and Y.-T. Jin, Aberrant promoter methylation of cell adhesion-related genes associated with clinicopathologic features in non-small cell lung cancer in China (2) 115–122
- Xu, R., F. Wang, L. Wu, J. Wang and C. Lu, A systematic review of hypermethylation of p16 gene in esophageal cancer (4) 215–226

- Xu, T., Q. Zou, J. Wu, B. Yu, Z. Xu, H. Cai and W. Zhang, Heterogeneous nuclear ribonucleoprotein U-like 1 and Poly (ADP-ribose) polymerase 1 are downregulated in renal cell carcinoma and connected with the prognosis (6) 411–415
- Xu, X., see Li, Z. (3) 181–192
- Xu, X., see Zhou, H.-T. (4) 281–288
- Xu, X.-L., Z.-Q. Ling, W. Chen, Y.-P. Xu and W.-M. Mao, The overexpression of VEGF in esophageal cancer is associated with a more advanced TMN stage: A meta-analysis (2) 105–113
- Xu, Y.-P., see Xu, X.-L. (2) 105–113
- Xu, Z., see Xu, T. (6) 411–415
- Xuan, S.-H., Y.-G. Zhou, J.-Q. Pan, W. Zhu and P. Xu, Overexpression of integrin α_V in the human nasopharyngeal carcinoma associated with metastasis and progression (5) 323–328
- Xue, Y., see Zhao, Y. (1) 59–66
- Yamano, S., see Hanada, S. (4) 289–298
- Yamano, S., see Komatsu, H. (3) 171–180
- Yan, H.-H., see Bai, X.-Y. (1) 37–47
- Yang, E.V. and T.D. Eubank, The impact of adrenergic signaling in skin cancer progression: Possible repurposing of β -blockers for treatment of skin cancer (3) 155–160
- Yang, H., see Wang, J. (2) 89–97
- Yang, I.-P., see Huang, M.-Y. (4) 269–279
- Yang, X., see Wang, G. (1) 21–28
- Yao, X., see Zhang, Y. (4) 299–305
- Yin, H., C. Lu, Y. Tang, H. Wang, H. Wang and J. Wang, Enhanced expression of EphrinB1 is associated with lymph node metastasis and poor prognosis in breast cancer (4) 261–267
- Yu, B., see Xu, T. (6) 411–415
- Yu, J., see Du, W. (6) 457–464
- Yuan, H., see Zhang, Y. (6) 483–489
- Yue, J., see Zhang, Y. (4) 299–305
- Zali, M., see Milanizadeh, S. (6) 427–432
- Zangar, R.C., see Jin, H. (3) 193–200
- Zeng, X., see Su, Y. (5) 367–375
- Zhang, B.L., see Li, Y.Y. (6) 471–481
- Zhang, C.-Y., see Xu, P.-W. (2) 115–122
- Zhang, G., see Li, Z. (3) 181–192
- Zhang, H., see Xu, P.-W. (2) 115–122
- Zhang, J., see Li, Y.Y. (6) 471–481
- Zhang, J.-Y., see Zhong, H. (1) 29–35
- Zhang, L., see Liu, S. (5) 345–349
- Zhang, Q., see Zhao, Y. (1) 59–66
- Zhang, S., see Nie, X. (6) 433–440
- Zhang, S., see Zhang, Y. (6) 483–489
- Zhang, T.-T., see Zhou, H.-T. (4) 281–288
- Zhang, W., see Li, Z. (3) 181–192
- Zhang, W., see Xu, T. (6) 411–415
- Zhang, X., see Li, Z. (3) 181–192
- Zhang, X., see Wang, P. (2) 123–130
- Zhang, X.-C., see Bai, X.-Y. (1) 37–47
- Zhang, Y., R. Wang, L. Zhu, S. Zhang, H. Yuan and H. Jiang, Meta-analysis of phospholipase C epsilon 1 polymorphism and cancer risk (6) 483–489
- Zhang, Y., see Su, Y. (5) 367–375
- Zhang, Y., see Zhou, H.-T. (4) 281–288
- Zhang, Y., X. Yao, C. Jiang, J. Yue, J. Guan, H. Cheng, M. Hajirashid, Y. Wang and L. Fan, Expression of PI3K, PTEN and Akt in small intestinal adenocarcinoma detected by quantum dots-based immunofluorescence technology (4) 299–305
- Zhang, Z., see Zhao, X. (1) 1–10
- Zhao, J., see Lv, M. (5) 395–401
- Zhao, J.Y., see Li, Y.Y. (6) 471–481
- Zhao, X., Z. Bai, P. Wu and Z. Zhang, S100P enhances the chemosensitivity of human gastric cancer cell lines (1) 1–10
- Zhao, Y., see Li, W. (5) 377–383
- Zhao, Y., Y. Xue, Q. Zhang, K. Wang and M. Lou, Transcriptional expression of glioma chemotherapy drugs associated marker molecules in gliomas and normal brain tissues (1) 59–66
- Zhao, Z., see Li, Z. (3) 181–192
- Zheng, B.-S., see Zhong, H. (1) 29–35
- Zheng, G.-X., see Zhong, H. (1) 29–35
- Zheng, S., see Liu, S. (5) 345–349
- Zhong, H., Y. Feng, G.-X. Zheng, Y. Liang, J.-Y. Zhang, B.-S. Zheng and X. Feng, A meta-analysis of the association between glutathione S-transferase P1 gene polymorphism and the risk of adenocarcinomas of lung cancer (1) 29–35
- Zhou, C., see Ju, L. (5) 329–336
- Zhou, H.-T., Z.-Z. Shi, Z.-X. Zhou, Y.-Y. Jiang, J.-J. Hao, T.-T. Zhang, F. Shi, X. Xu, M.-R. Wang and Y. Zhang, Genomic changes in rectal adenocarcinoma associated with liver metastasis (4) 281–288
- Zhou, J., see Wang, G. (1) 21–28
- Zhou, Y., see Wang, W. (5) 351–357
- Zhou, Y.-G., see Xuan, S.-H. (5) 323–328
- Zhou, Z.-X., see Zhou, H.-T. (4) 281–288
- Zhu, L., see Zhang, Y. (6) 483–489
- Zhu, P., see Liu, S. (5) 345–349
- Zhu, W., see Xuan, S.-H. (5) 323–328
- Zhu, X., see Lv, M. (5) 395–401
- Zhu, Z., see Jiang, L. (6) 465–470
- Zhuo, J., see Wang, X. (2) 81–88
- Ziglioli, F., see Gallotta, A. (4) 227–234
- Zou, Q., see Xu, T. (6) 411–415